FDA Approves Moderna's RSV Vaccine for Younger At-Risk Adults

The US Food and Drug Administration (FDA) on June 12 expanded the use of Moderna's respiratory syncytial virus (RSV) vaccine to a younger group of adults aged 18 to 59 who are at increased risk of disease.

- 

MARYLAND – The US Food and Drug Administration (FDA) on June 12 expanded the use of Moderna's respiratory syncytial virus (RSV) vaccine to a younger group of adults aged 18 to 59 who are at increased risk of disease.

Moderna's RSV shot, mRESVIA, was the first non-Covid-19 messenger RNA-based (mRNA) vaccine to be approved in the US.

The shot, the company's second product, is already approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older.

While the FDA approval is a necessary step, the US Centers for Disease Control and Prevention (CDC) still has to recommend the shots before they are available for the age group.